Skip to content

Ashland

US · ASH #2461 by market cap Listed 1970
72.40 -1.72 -2.32%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Revenue Concentration how this is computed

Diversified
  • Life sciences is the largest reported line at 36.22% of revenue, across 5 reported segments.
  • No single line clears half of revenue; Personal Care is next at 31.19%, spreading the business across more than one real driver.

Revenue annual, last 8 years

Latest year +2.14% YoY

Margins

Gross margin
32.26%
Operating margin
5.85%
Net margin
0.21%

Key ratios & quality

Income statement

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Revenue 2.15B2.02B2.11B2.39B2.19B2.11B1.82B1.86B
Gross profit 651.00M599.00M670.00M830.00M668.00M618.00M549.00M601.00M
Selling & admin expenses 426.00M400.00M358.00M393.00M365.00M404.00M344.00M377.00M
Research & development 58.00M56.00M50.00M55.00M51.00M55.00M54.00M55.00M
Operating profit 82.00M59.00M172.00M288.00M159.00M83.00M88.00M109.00M
Pretax profit -9.00M-577.00M135.00M206.00M160.00M-24.00M-809.00M69.00M
Tax 30.00M-22.00M-38.00M25.00M-8.00M-223.00M13.00M44.00M
Net profit 505.00M-508.00M220.00M927.00M178.00M169.00M-845.00M4.00M
Basic EPS 8-841733-180
Diluted EPS 8.15-8.393.5916.413.313.36-18.230.09

Balance sheet

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Total current assets 1.43B1.55B1.72B1.77B1.51B1.20B1.21B1.34B
Cash & ST investments 232.00M454.00M210.00M646.00M417.00M300.00M215.00M480.00M
Inventory 597.00M506.00M473.00M629.00M626.00M545.00M568.00M482.00M
Total assets 7.25B6.88B6.61B6.21B5.94B5.65B4.61B4.53B
Total current liabilities 757.00M813.00M934.00M553.00M456.00M490.00M423.00M452.00M
Short-term debt 166.00M302.00M397.00M19.00M38.00M20.00M21.00M22.00M
Long-term debt 1.50B1.57B1.60B1.27B1.31B1.35B1.38B1.37B
Total liabilities 3,680,000,000.003,841,000,000.003,860,000,000.002,993,000,000.002,842,000,000.002,777,000,000.002,707,000,000.002,679,000,000.00
Total equity 3.57B3.04B2.75B3.22B3.10B2.87B1.90B1.85B
Retained earnings 3.22B2.65B2.80B3.65B3.60B3.32B2.30B--

Cash flow

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Operating cash flow 241.00M203.00M560.00M-213.00M243.00M411.00M94.00M339.00M
Depreciation & amortization 277.00M235.00M244.00M241.00M243.00M274.00M237.00M185.00M
Free cash flow 94.00M70.00M455.00M-326.00M73.00M274.00M-4.00M251.00M
Dividends paid -64.00M-66.00M-70.00M-70.00M-76.00M-78.00M-76.00M-76.00M
Stock buybacks / issuance -200.00M0-450.00M-200.00M-300.00M-380.00M-100.00M0
Ending cash balance 232.00M454.00M210.00M646.00M417.00M300.00M215.00M480.00M

Returns & efficiency

Line item 2019 2020 2021 2022 2023 2024 2025 2026
ROE % 14.48-15.387.6031.045.645.67-35.410.21
ROA % 6.51-7.193.2614.462.932.92-16.480.09
ROIC % 10.50-8.235.4520.684.574.52-20.780.12
5-year avg ROE % 5.260.312.028.228.686.912.91--
EBIT margin % 7.38-17.849.6611.219.771.37-41.015.85
FCF / sales % 3.492.7921.55--3.3312.97--13.47
Current ratio 1.891.901.843.203.302.442.852.96
Quick ratio 0.941.100.621.901.661.111.081.65
Debt / assets 22.9928.9231.8122.2624.5526.0132.3132.52
LT debt / equity 42.0355.5761.9942.3645.8550.4977.1578.46
Interest coverage 1.61-4.722.964.323.960.55-12.26--
Revenue CAGR (3Y) % -10.73-4.42-6.583.642.810.03-8.63-5.26
Net income CAGR (3Y) % ----24.5022.44---8.42---71.78
FCF CAGR (3Y) % -40.53-31.2148.12--1.41-15.55--50.93

Revenue breakdown most recent period

Business

Life sciences36.22%
Personal Care31.19%
Specialty Additives27.36%
Intermediates7.44%

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Ashland discussion 0 comments

Add a comment